KA2237 is a potent, dual-selective inhibitor of the p110β and p110δ isoforms of PI3K. This drug has a combined targeted and immunotherapeutic mode of action. It inhibits oncogenic pathways within cancer cells, and drives immunotherapeutic activity within the tumor microenvironment. Its selectivity for p110β and p110δ reduces the potential for side effects connected to p110α and p110γ inhibition.
KA2507 is a potent and selective inhibitor of HDAC6. Selective HDAC6 inhibition promotes tumor cell apoptosis by suppressing aggresome formation and also drives immunotherapeutic inhibition of cancer cell proliferation by modulating key tumor microenvironment markers, including by downregulating the expression of programmed death ligand-1 (PD-L1).